Description

Endoscopic improvement rates in ulcerative colitis patients receiving curcumin as adjuvant therapy are pooled. Combined results favor curcumin supplementation over placebo.

Figure 3

Forest Plot

Source Paper

Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Nutrients (2018)

PMID: 30424514

DOI: 10.3390/nu10111737

Cite This Figure

![Figure 3: Endoscopic improvement rates in ulcerative colitis patients receiving curcumin as adjuvant therapy are pooled. Combined results favor curcumin supplementation over placebo.]()

> Source: Maria G Grammatikopoulou et al. "Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Co." *Nutrients*, 2018. PMID: [30424514](https://pubmed.ncbi.nlm.nih.gov/30424514/)

<figure>
  <img src="" alt="Endoscopic improvement rates in ulcerative colitis patients receiving curcumin as adjuvant therapy are pooled. Combined results favor curcumin supplementation over placebo." />
  <figcaption>Figure 3. Endoscopic improvement rates in ulcerative colitis patients receiving curcumin as adjuvant therapy are pooled. Combined results favor curcumin supplementation over placebo.<br>  Source: Maria G Grammatikopoulou et al. "Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Co." <em>Nutrients</em>, 2018. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/30424514/">30424514</a></figcaption>
</figure>

Related Evidence

Curcumin for Ulcerative Colitis (UC)

Grade B · 5 studies